HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maresin 1 mitigates LPS-induced acute lung injury in mice.

AbstractBACKGROUND AND PURPOSE:
Acute lung injury (ALI) is a severe illness with a high rate of mortality. Maresin 1 (MaR1) was recently reported to regulate inflammatory responses. We used a LPS-induced ALI model to determine whether MaR1 can mitigate lung injury.
EXPERIMENTAL APPROACH:
Male BALB/c mice were injected, intratracheally, with either LPS (3 mg·kg(-1) ) or normal saline (1.5 mL·kg(-1) ). After this, normal saline, a low dose of MaR1 (0.1 ng per mouse) or a high dose of MaR1 (1 ng per mouse) was given i.v. Lung injury was evaluated by detecting arterial blood gas, pathohistological examination, pulmonary oedema, inflammatory cell infiltration, inflammatory cytokines in the bronchoalveolar lavage fluid and neutrophil-platelet interactions.
KEY RESULTS:
The high dose of MaR1 significantly inhibited LPS-induced ALI by restoring oxygenation, attenuating pulmonary oedema and mitigating pathohistological changes. A combination of elisa and immunohistochemistry showed that high-dose MaR1 attenuated LPS-induced increases in pro-inflammatory cytokines (TNF-α, IL-1β and IL-6), chemokines [keratinocyte chemokine, monocyte chemoattractant protein-5, macrophage inflammatory protein (MIP)-1α and MIP-1γ], pulmonary myeloperoxidase activity and neutrophil infiltration in the lung tissues. Consistent with these observations, flow cytometry and Western blotting indicated that MaR1 down-regulated LPS-induced neutrophil adhesions and suppressed the expression of intercellular adhesion molecule (ICAM)-1, P-selection and CD24.
CONCLUSIONS AND IMPLICATIONS:
High-dose MaR1 mitigated LPS-induced lung injury in mice by inhibiting neutrophil adhesions and decreasing the levels of pro-inflammatory cytokines.
AuthorsJie Gong, Zhou-yang Wu, Hong Qi, Lin Chen, Hong-bin Li, Bo Li, Cheng-ye Yao, Ya-xin Wang, Jing Wu, Shi-ying Yuan, Shang-long Yao, You Shang
JournalBritish journal of pharmacology (Br J Pharmacol) Vol. 171 Issue 14 Pg. 3539-50 (Jul 2014) ISSN: 1476-5381 [Electronic] England
PMID24697684 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2014 The British Pharmacological Society.
Chemical References
  • 7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid
  • Inflammation Mediators
  • Lipopolysaccharides
  • Docosahexaenoic Acids
Topics
  • Acute Lung Injury (chemically induced, drug therapy, pathology)
  • Administration, Inhalation
  • Animals
  • Cell Adhesion (drug effects)
  • Docosahexaenoic Acids (administration & dosage, pharmacology)
  • Inflammation Mediators (metabolism)
  • Lipopolysaccharides (administration & dosage, antagonists & inhibitors, toxicity)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Neutrophils (drug effects, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: